Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | RAF1 | P04049 | 5/20 | 0.42 |
| ▸ | BRAF | P15056 | 5/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.41 |
| ▸ | TUBB | P07437 | 3/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mebendazole SCHEMBL9837685 | 0.88 | METAP1 (0.64) | METAP1CYP1A2HIF1ALMNAKDR | |
| Cambendazole SCHEMBL44000 | 0.85 | METAP1 (0.48) | METAP1CYP1A2HIF1AALDH1A1CYP2C9 | |
| Cambendazole SCHEMBL29409263 | 0.85 | METAP1 (0.48) | METAP1CYP1A2HIF1AALDH1A1CYP2C9 | |
| Cambendazole SCHEMBL8734398 | 0.84 | METAP1 (0.57) | METAP1CYP1A2HIF1AALDH1A1MAPK1 | |
| SCHEMBL3500748 | 0.81 | METAP1 (0.52) | METAP1CYP1A2HIF1AALDH1A1ADORA3 | |
| Cambendazole SCHEMBL2895694 | 0.78 | METAP1 (0.55) | METAP1CYP1A2HIF1AALDH1A1ADORA3 | |
| Carbendazim SCHEMBL18131962 | 0.78 | METAP1 (0.65) | METAP1CYP1A2HIF1ALMNAKDR | |
| Mebendazole SCHEMBL3429179 | 0.77 | ABL1 (0.82) | CYP1A2HIF1ALMNAKDRALDH1A1 | |
| Mebendazole SCHEMBL29409261 | 0.77 | ABL1 (0.82) | CYP1A2HIF1ALMNAKDRALDH1A1 | |
| Mebendazole SCHEMBL15860 | 0.77 | ABL1 (0.82) | CYP1A2HIF1ALMNAKDRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3260135-A1 | TREATMENT OR PREVENTION OF INFECTION | Oral Health Australia Pty Ltd (AU) | 2017-12-27 | — | — | EP | disclosed |
| US-9125853-B2 | Treatment or prevention of infection | ORAL HEALTH AUSTRALIA PTY LTD (AU) | 2015-09-08 | — | — | US | disclosed |
| US-8895019-B2 | Biofilm treatment | ORAL HEALTH AUSTRALIA PTY LTD (AU) | 2014-11-25 | — | — | US | disclosed |
| EP-2638905-A2 | Biofilm treatment | Oral Health Australia Pty Ltd (AU) | 2013-09-18 | — | — | EP | disclosed |
| US-20130129768-A1 | TREATMENT OR PREVENTION OF INFECTION | ORAL HEALTH AUSTRALIA PTY LTD (AU) | 2013-05-23 | — | — | US | disclosed |
| EP-2175851-B1 | BIOFILM TREATMENT | ORAL HEALTH AUSTRALIA PTY LTD (AU) | 2013-05-15 | — | — | EP | disclosed |
| US-20130028847-A1 | BIOFILM TREATMENT | ORAL HEALTH AUSTRALIA PTY LTD | 2013-01-31 | — | — | US | disclosed |
| EP-2538970-A1 | TREATMENT OR PREVENTION OF INFECTION | Oral Health Australia Pty Ltd (AU) | 2013-01-02 | — | — | EP | disclosed |
| US-8241611-B2 | Biofilm treatment | Oral Health Austrailia Pty. Ltd. (AU) | 2012-08-14 | — | — | US | disclosed |
| WO-2011103633-A1 | TREATMENT OR PREVENTION OF INFECTION | ORAL HEALTH AUSTRALIA PTY LTD (AU) | 2011-09-01 | — | — | WO | disclosed |
| US-20100209362-A1 | Biofilm Treatment | ORAL HEALTH AUSTRALIA PTY LTD. | 2010-08-19 | — | — | US | disclosed |
| EP-2175851-A1 | BIOFILM TREATMENT | Oral Health Australia Pty Ltd (AU) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009006699-A1 | BIOFILM TREATMENT | ORAL HEALTH AUSTRALIA PTY LTD (AU) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209362-A1 | Biofilm Treatment | TIMP3, FGB, SERPINB1 | METAP1 132/4885CYP1A2 3420/4885HIF1A 583/4885 |
| US-20130028847-A1 | BIOFILM TREATMENT | TIMP3, FGB, SERPINB1 | METAP1 132/4885CYP1A2 3420/4885HIF1A 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.